Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Genomic Profiling in Cancer Patients

NCT01775072 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not inherited (passed down from parents) but happen after birth in the cancer itself. Most cancers have many mutations. Some of these mutations are important for the cancer cells to survive while others are not. The goal of this study is test cancer for certain mutations using leftover tumor tissue from a previous surgery or biopsy. Participants will also be asked to provide a tube of blood cheek (also known as a buccal) swab, or a saliva sample that contains normal genes for comparison. The purpose of Part B of this study is to: Understand how genetic changes in tumor effect the chance of responding to experimental cancer treatment. Understand how the genes in the tumor change overtime in response to targeted cancer treatment.

Interventions

  • GENETIC molecular profiling of tumors
  • GENETIC Clinical Germline Analysis

Study Locations (18)

New York

  • Kings County Hopsital Center — Brooklyn
  • Memorial Sloan Kettering Cancer Commack — Commack
  • Memorial Sloan Kettering Westchester — Harrison
  • Queens Cancer Center of Queens Hospital — Jamaica
  • Metropolitan Hospital Center — New York
  • Ralph Lauren Center for Cancer Care and Prevention — New York
  • Memorial Sloan Kettering Cancer Center — New York
  • Medisys Health Network (Data Collection Only) — Richmond Hill
  • NYC Health & Hospitals /Lincoln Medical Center — The Bronx
  • Memorial Sloan Kettering Nassau — Uniondale

Connecticut

  • St. Vincent (Data Collection Only) — Bridgeport
  • Hartford Healthcare Cancer Institute @ Hartford Hospital — Hartford
  • Norwalk Hospital — Norwalk

New Jersey

  • Memorial Sloan Kettering Basking Ridge — Basking Ridge
  • Memorial Sloan Kettering Monmouth — Middletown
  • Memorial Sloan Kettering Bergen — Montvale

Florida

  • Baptist Alliance MCI — Miami

Pennsylvania

  • Lehigh Valley Health Network — Allentown

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2013-01
Est. Completion 2027-01

Sponsor

Memorial Sloan Kettering Cancer Center

2,280 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01775072

The ClinicalTrials.gov registry entry for NCT01775072 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 2,280 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions — of which molecular profiling of tumors is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01775072 reports 18 study locations spanning 5 distinct geographic areas — top geographies include New York, Connecticut, New Jersey. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01775072 about?

NCT01775072 is a clinical study titled "Genomic Profiling in Cancer Patients". The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not inherited (passed down from parents) but happen after birth in the cancer itself. Most cancers have many mutations. Som...

What is the current status of trial NCT01775072?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2013-01. Estimated completion is 2027-01.

What conditions does trial NCT01775072 study?

This clinical trial studies the following conditions: Solid Tumors, Hematologic Cancers. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01775072?

The interventions under investigation include: molecular profiling of tumors (GENETIC), Clinical Germline Analysis (GENETIC). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01775072?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 2,280 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01775072 being conducted?

This trial has 18 study locations across Connecticut, Florida, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial